alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › drug-development

drug-development

3 studies tagged drug-development, dated 2007-09-04 to 2023-03-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development 2023-03-01
  2. The Alzheimer's disease drug development landscape 2021-11-11
  3. Impact of amyloid imaging on drug development in Alzheimer's disease 2007-09-04

Studies

3 studies carry this tag.

Date range

2007 to 2023

Top journals

  • Alzheimer's research & therapy 1
  • Lancet regional health. Americas 1
  • Nuclear medicine and biology 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Lancet regional health. Americas 2023-03-01 Treatments

    In 2021, the US Food and Drug Administration (FDA) granted approval to aducanumab, an antiamyloid antibody for early-stage Alzheimer's disease, despite a lack of clear clinical evidence demonstrating the drug's cognitive benefits.

  2. The Alzheimer's disease drug development landscape

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Alzheimer's research & therapy 2021-11-11 Treatments

    The field has made significant progress over the last 15 years.

  3. Impact of amyloid imaging on drug development in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Nuclear medicine and biology 2007-09-04 Treatments

    Imaging agents capable of assessing amyloid-beta (Abeta) content in vivo in the brains of Alzheimer's disease (AD) subjects likely will be important as diagnostic agents to detect Abeta plaques in the brain as well as to help test the amyloid cascade hypothesis of AD and as an aid to assess the efficacy of anti-amyloid therapeutics currently under development and in clinical trials.

All topic tags with their study counts